CD19-CD22 CAR-T cells (CD19 scFv-CD22 scFv-TM-41BB-CD3z)

CD19 is a type I membrane protein expressed by all B cells and B cell precursors but not by plasma cells or other cell types. CD19 functions as part of the B cell antigen receptor complex, allowing B cells to respond to foreign antigens. CD19 is also expressed on all B cell malignancies and is a favorable target for immunotherapy because of its specificity; patients receive immunoglobulin injections because their own B cells are depleted along with the malignant cells. CD22 is a type 1 membrane glycoprotein expressed on B cells and B cell cancers. A member of the SIGLEC family of lectins, CD22 mediates cell-cell interactions and regulates B cell activation. 

ProMab's PM-CAR1035 primary human CAR-T cells express a tandem CAR with anti-CD19 and anti-CD22 scFvs, hinge and transmembrane domains, the 4-1BB costimulatory domain and the CD3zeta activation domain. The CAR-T cells are generated by transducing activated human T cells with replication-defective lentivirus encoding the CAR. After expansion, the cells are cryopreserved and shipped in vials containing up to 10 million cells. Please inquire for orders over 10 million cells. All ProMab cells are guaranteed to be sterile, pathogen-free and mycoplasma-free.